{"id":611307,"date":"2022-08-09T17:44:01","date_gmt":"2022-08-09T17:44:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=611307"},"modified":"2022-08-09T17:44:01","modified_gmt":"2022-08-09T17:44:01","slug":"warm-autoimmune-hemolytic-anemia-waiha-pipeline-analysis-clinical-and-nonclinical-trials-moa-emerging-therapies-and-treatment-algorithm-companies-immunovant-alexion-rigel-pharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/warm-autoimmune-hemolytic-anemia-waiha-pipeline-analysis-clinical-and-nonclinical-trials-moa-emerging-therapies-and-treatment-algorithm-companies-immunovant-alexion-rigel-pharma_611307.html","title":{"rendered":"Warm Autoimmune Hemolytic Anemia (Waiha) Pipeline Analysis | Clinical and Non-Clinical Trials, MOA, Emerging Therapies, And Treatment Algorithm | Companies &#8211; Immunovant, Alexion, Rigel Pharma"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1660017631.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Warm Autoimmune Hemolytic Anemia (Waiha) Pipeline Analysis | Clinical and Non-Clinical Trials, MOA, Emerging Therapies, And Treatment Algorithm | Companies - Immunovant, Alexion, Rigel Pharma\" src=\"https:\/\/www.abnewswire.com\/uploads\/1660017631.jpeg\" alt=\"Warm Autoimmune Hemolytic Anemia (Waiha) Pipeline Analysis | Clinical and Non-Clinical Trials, MOA, Emerging Therapies, And Treatment Algorithm | Companies - Immunovant, Alexion, Rigel Pharma\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Warm Autoimmune Hemolytic Anemia (Waiha) Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><em>&ldquo;Warm Autoimmune Hemolytic Anemia (WAIHA) Pipeline Insight, 2022&Prime; report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Warm Autoimmune Hemolytic Anemia Market.<\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The&nbsp;<strong>Warm Autoimmune Hemolytic Anemia Pipeline<\/strong>&nbsp;report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The report also covers a detailed description of the drug including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/bbbdeb48d327b394f7939041af586bc0.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/warm-autoimmune-hemolytic-anemia-waiha-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Warm Autoimmune Hemolytic Anemia (WAIHA) Pipeline Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the&nbsp;<strong>treatment of Warm Autoimmune Hemolytic Anemia<\/strong>&nbsp;with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Warm Autoimmune Hemolytic Anemia Treatment.<\/li>\n<li><strong>Warm Autoimmune Hemolytic Anemia key companies<\/strong>&nbsp;involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li><strong>Warm Autoimmune Hemolytic Anemia Drugs<\/strong>&nbsp;under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the&nbsp;<strong>Warm Autoimmune Hemolytic Anemia market<\/strong>.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report &ndash;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/warm-autoimmune-hemolytic-anemia-waiha-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/warm-autoimmune-hemolytic-anemia-waiha-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Warm Autoimmune Hemolytic Anemia (WAIHA) Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\">As per DelveInsight&rsquo;s estimation, the future of WAIHA treatment is continuing to trend toward complement inhibitors, Syk kinase inhibitors, and FcRn receptor antagonist Mab. If these therapies are ultimately successfully commercialized, they have the potential to transform the current standard of care for WAIHA patients.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key companies in the Warm Autoimmune Hemolytic Anemia (WAIHA) Market include:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Rigel Pharmaceuticals<\/li>\n<li>Apellis Pharmaceuticals<\/li>\n<li>Momenta Pharmaceuticals<\/li>\n<li>Alexion<\/li>\n<li>Immunovant<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And many others.<\/p>\n<p style=\"text-align: justify;\"><strong><em>Currently, there are no approved therapies for the management of WAIHA with only one-third of the patients maintaining sustained disease control once steroids are discontinued.<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Warm Autoimmune Hemolytic Anemia (WAIHA) Therapies covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Fostamitinib<\/li>\n<li>APL-2<\/li>\n<li>M281<\/li>\n<li>IMVT-1401<\/li>\n<li>ALXN1830<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And many others.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Get More Detailed Insights Into the Emerging Therapies &amp; Key Companies &ndash;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/warm-autoimmune-hemolytic-anemia-waiha-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/warm-autoimmune-hemolytic-anemia-waiha-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><em>As per DelveInsight, the&nbsp;<strong>Warm Autoimmune Hemolytic Anemia (WAIHA) Therapeutics Market<\/strong>&nbsp;is anticipated to grow in the coming years owing to the&nbsp;<strong>rise&nbsp;in the prevalent population of WAIHA<\/strong>&nbsp;and&nbsp;<strong>launch of emerging therapies<\/strong>.<\/em><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Warm Autoimmune Hemolytic Anemia Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">4. Warm Autoimmune Hemolytic Anemia &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. Warm Autoimmune Hemolytic Anemia Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Warm Autoimmune Hemolytic Anemia Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Warm Autoimmune Hemolytic Anemia Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Warm Autoimmune Hemolytic Anemia Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Warm Autoimmune Hemolytic Anemia Product Profiles<\/p>\n<p style=\"text-align: justify;\">14. Key Companies in the Warm Autoimmune Hemolytic Anemia Market<\/p>\n<p style=\"text-align: justify;\">15. Key Products in the Warm Autoimmune Hemolytic Anemia Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. Warm Autoimmune Hemolytic Anemia Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Warm Autoimmune Hemolytic Anemia Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Warm Autoimmune Hemolytic Anemia Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample PDF Report &ndash;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/warm-autoimmune-hemolytic-anemia-waiha-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/warm-autoimmune-hemolytic-anemia-waiha-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Other Trending Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/exophthalmos-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Exophthalmos Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">Exophthalmos Market Research Report present a detailed analysis of the market listing Exophthalmos Epidemiology, Drug therapies and pipeline for study period from 2019-2032.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight <\/strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=warm-autoimmune-hemolytic-anemia-waiha-pipeline-analysis-clinical-and-nonclinical-trials-moa-emerging-therapies-and-treatment-algorithm-companies-immunovant-alexion-rigel-pharma\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/warm-autoimmune-hemolytic-anemia-waiha-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/warm-autoimmune-hemolytic-anemia-waiha-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/warm-autoimmune-hemolytic-anemia-waiha-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=warm-autoimmune-hemolytic-anemia-waiha-pipeline-analysis-clinical-and-nonclinical-trials-moa-emerging-therapies-and-treatment-algorithm-companies-immunovant-alexion-rigel-pharma\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Warm Autoimmune Hemolytic Anemia (Waiha) Pipeline &ldquo;Warm Autoimmune Hemolytic Anemia (WAIHA) Pipeline Insight, 2022&Prime; report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Warm Autoimmune Hemolytic Anemia Market. &nbsp; The&nbsp;Warm Autoimmune Hemolytic &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/warm-autoimmune-hemolytic-anemia-waiha-pipeline-analysis-clinical-and-nonclinical-trials-moa-emerging-therapies-and-treatment-algorithm-companies-immunovant-alexion-rigel-pharma_611307.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,423,413],"tags":[],"class_list":["post-611307","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/611307","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=611307"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/611307\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=611307"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=611307"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=611307"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}